Literature DB >> 9849496

Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy.

O Merimsky, I Meller, Y Kollender, M Inbar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849496

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  6 in total

1.  Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs.

Authors:  Carlos O Rodriguez; Torrie A Crabbs; Dennis W Wilson; Virginia A Cannan; Katherine A Skorupski; Nancy Gordon; Nadya Koshkina; Eugenie Kleinerman; Peter M Anderson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-08       Impact factor: 2.849

2.  An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.

Authors:  J T Hartmann; K Oechsle; J Huober; A Jakob; M Azemar; M Horger; L Kanz; C Bokemeyer
Journal:  Invest New Drugs       Date:  2006-05       Impact factor: 3.651

3.  Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.

Authors:  Gonzalo Lopez; Danielle Braggio; Abeba Zewdu; Lucia Casadei; Kara Batte; Hemant Kumar Bid; David Koller; Peter Yu; Obiajulu Hans Iwenofu; Anne Strohecker; Edwin Choy; Dina Lev; Raphael Pollock
Journal:  PLoS One       Date:  2017-11-29       Impact factor: 3.240

4.  Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models.

Authors:  Joshua D Schoenfeld; Zita A Sibenaller; Kranti A Mapuskar; Megan D Bradley; Brett A Wagner; Garry R Buettner; Varun Monga; Mohammed Milhem; Douglas R Spitz; Bryan G Allen
Journal:  Redox Biol       Date:  2017-09-28       Impact factor: 11.799

5.  Gemcitabine in bone sarcoma resistant to Doxorubicin-based chemotherapy.

Authors:  O Merimsky; I Meller; Y Kollender; J Issakov; G Flusser; M Inbar
Journal:  Sarcoma       Date:  2000

6.  Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute.

Authors:  Wen-Xi Yu; Li-Na Tang; Feng Lin; Yang Yao; Zan Shen
Journal:  Oncol Lett       Date:  2014-08-21       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.